John D. Horowitz

List of Publications by Year
in descending order

149 papers	14,910 citations	76294 40 h-index	18633 119 g-index
152 all docs	152 docs citations	152 times ranked	13890 citing authors

#	Article	IF	Citations
1	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. Clinical Research in Cardiology, 2022, 111, 186-196.	1.5	8
2	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 227-235.	1.4	6
3	Contextualising evidence based medicine in determining the key root for translational effectiveness for chronic disease self-management and heart failure. Reviews in Cardiovascular Medicine, 2022, 23, 1.	0.5	0
4	Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: Mechanisms and Clinical Implications in Cardiovascular Disease. International Journal of Molecular Sciences, 2022, 23, 1042.	1.8	13
5	The Antianginal Drug Perhexiline Displays Cytotoxicity against Colorectal Cancer Cells In Vitro: A Potential for Drug Repurposing. Cancers, 2022, 14, 1043.	1.7	9
6	Assessment of Artificial Intelligence in Echocardiography Diagnostics in Differentiating Takotsubo Syndrome From Myocardial Infarction. JAMA Cardiology, 2022, 7, 494.	3.0	18
7	Cardioprotective actions of nitroxyl donor Angeli's salt are preserved in the diabetic heart and vasculature in the face of nitric oxide resistance. British Journal of Pharmacology, 2022, 179, 4117-4135.	2.7	4
8	Transdiagnostic Cognitive-Behavioral Therapy for Depression and Anxiety Disorders in Cardiovascular Disease Patients: Results From the CHAMPS Pilot-Feasibility Trial. Frontiers in Psychiatry, 2022, 13, 741039.	1.3	4
9	Editorial Commentary: Takotsubo syndrome: A key role for inflammation?. Trends in Cardiovascular Medicine, 2021, 31, 231-232.	2.3	3
10	Takotsubo Syndrome: Finally Emerging From the Shadows?. Heart Lung and Circulation, 2021, 30, 36-44.	0.2	13
11	Impairment of platelet NO signalling in coronary artery spasm: role of hydrogen sulphide. British Journal of Pharmacology, 2021, 178, 1639-1650.	2.7	11
12	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Failure, 2021, 8, 1924-1932.	1.4	8
13	Incidence and clinical/laboratory correlates of early hypotension in takotsubo syndrome. ESC Heart Failure, 2021, 8, 2009-2015.	1.4	4
14	Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry. Journal of the American Heart Association, 2021, 10, e014059.	1.6	18
15	Letter by Nguyen et al Regarding Article, â€œCoronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Womenâ€. Circulation, 2021, 144, e205.	1.6	0
16	Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial). American Heart Journal, 2021, 240, 101-113.	1.2	14
17	Angina due to coronary artery spasm (variant angina): diagnosis and intervention strategies. Expert Review of Cardiovascular Therapy, 2021, 19, 917-927.	0.6	7
18	Abstract P405: Cardioprotective Actions Of Nitroxyl Donor Angeli's Salt Are Preserved In The Diabetic Heart And Vasculature In The Face Of Nitric Oxide Resistance. Circulation Research, 2021, 129, .	2.0	0

#	Article	IF	Citations
19	Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice. Current Cardiology Reviews, 2021, 17, e160721187934.	0.6	3
20	The unspoken benefit of participation in a clinical trial. Clinical Medicine, 2021, 21, e645-e647.	0.8	3
21	Clinical correlates and prognostic impact of neurologic disorders in Takotsubo syndrome. Scientific Reports, 2021, 11, 23555.	1.6	13
22	Inorganic nitrate and nitrite supplementation fails to improve skeletal muscle mitochondrial efficiency in mice and humans. American Journal of Clinical Nutrition, 2020, 111, 79-89.	2.2	16
23	Endothelial dysfunction and glycocalyx shedding in heart failure: insights from patients receiving cardiac resynchronisation therapy. Heart and Vessels, 2020, 35, 197-206.	0.5	6
24	Nitric Oxide Resistance, Induced in the Myocardium by Diabetes, Is Circumvented by the Nitric Oxide Redox Sibling, Nitroxyl. Antioxidants and Redox Signaling, 2020, 32, 60-77.	2.5	18
25	Impact of aspirin on takotsubo syndrome: a propensity scoreâ€based analysis of the InterTAK Registry. European Journal of Heart Failure, 2020, 22, 330-337.	2.9	24
26	Matrix metalloproteinase-2 activation: critical to myocardial contractile dysfunction following ischaemiaâ€“reperfusion. Cardiovascular Research, 2020, 116, 876-878.	1.8	4
27	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 279-287.	1.1	34
28	The N-AcetylCysteine and RAMipril in Takotsubo Syndrome Trial (NACRAM): Rationale and design of a randomised controlled trial of sequential N-Acetylcysteine and ramipril for the management of Takotsubo Syndrome. Contemporary Clinical Trials, 2020, 90, 105894.	0.8	14
29	Prognostic value of texture analysis from cardiac magnetic resonance imaging in patients with Takotsubo syndrome: a machine learning based proof-of-principle approach. Scientific Reports, 2020, 10, 20537.	1.6	9
30	Does high on-treatment platelet aggregability reflect poor individual response to clopidogrel?. Thrombosis Research, 2020, 196, 510-515.	0.8	4
31	Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NOâ€¢) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation. Handbook of Experimental Pharmacology, 2020, 264, 311-337.	0.9	7
32	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268.	1.0	49
33	Serial measurement of interleukinâ€6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and REâ€LY trials. Journal of Thrombosis and Haemostasis, 2020, 18, 2287-2295.	1.9	14
34	Nitroxyl: A Novel Strategy to Circumvent Diabetes Associated Impairments in Nitric Oxide Signaling. Frontiers in Pharmacology, 2020, 11, 727.	1.6	15
35	Prolonged suppression of the antiâ€oxidant/antiâ€inflammatory effects of BNP postâ€Takotsubo syndrome. ESC Heart Failure, 2020, 7, 2250-2257.	1.4	2
36	The Heart Failure with Preserved Ejection Fraction Conundrumâ€"Redefining the Problem and Finding Common Ground?. Current Heart Failure Reports, 2020, 17, 34-42.	1.3	12

#	Article	IF	Citations
37	Incremental â€œTherapeuticâ€•Myocardial Exposure to Catecholamines: Incidence and Impact in Takotsubo Syndrome. Cardiovascular Drugs and Therapy, 2020, 34, 95-100.	1.3	4
38	Diabetes-induced myocardial NOâ€¢ resistance, is circumvented by the nitric oxide (NO) redox sibling, nitroxyl, HNO. Journal of Molecular and Cellular Cardiology, 2020, 140, 9.	0.9	0
39	Increased Rate of Hospitalization With Prinzmetal Angina: What Exactly Is Happening?. American Journal of Medicine, 2020, 133, e162-e163.	0.6	1
40	Age-Related Variations in Takotsubo Syndrome. Journal of the American College of Cardiology, 2020, 75, 1869-1877.	1.2	42
41	N-ACETYLCYSTEINE REVERSES PEROXYNITRITE AND HYDROGEN PEROXIDE-INDUCED APOPTOSIS OF HUMAN MYOCARDIAL CELLS. Journal of the American College of Cardiology, 2019, 73, 1022.	1.2	0
42	Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e010881.	1.6	63
43	Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e011194.	1.6	27
44	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. Circulation, 2019, 139, 413-415.	1.6	75
45	Prediction of shortâ€•and longâ€•term mortality in takotsubo syndrome: the InterTAK Prognostic Score. European Journal of Heart Failure, 2019, 21, 1469-1472.	2.9	20
46	Interactions Between Influenza and Heart Failure Hospitalizationsâ€”Diagnostic and Pathogenetic Issues. JAMA Cardiology, 2019, 4, 949.	3.0	1
47	Takotsubo Syndrome Identified in the Intensive Care Unit: A Prospective Observational Study. Australian Critical Care, 2019, 32, S17.	0.6	0
48	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. European Heart Journal, 2019, 40, 2142-2151.	1.0	79
49	Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. Journal of Thrombosis and Thrombolysis, 2019, 47, 345-352.	1.0	13
50	Antecedent cancer in Takotsubo syndrome predicts both cardiovascular and long-term mortality. Cardio-Oncology, 2019, 5, 20.	0.8	5
51	Electrical remodelling post cardiac resynchronization therapy in patients with ischemic and non-ischemic heart failure. Journal of Electrocardiology, 2019, 53, 44-51.	0.4	2
52	Neutrophil-Initiated Myocardial Inflammation and Its Modulation by B-Type Natriuretic Peptide: A Potential Therapeutic Target. International Journal of Molecular Sciences, 2019, 20, 129.	1.8	6
53	Risk stratification for coronary artery disease in multi-ethnic populations: Are there broader considerations for cost efficiency?. World Journal of Methodology, 2019, 9, 1-19.	1.1	8
54	Risk indexation and atrial fibrillation. Aging, 2019, 11, 1607-1608.	1.4	0

#	Article	IF	Citations
55	Does cardiac resynchronization therapy restore peripheral circulatory homeostasis?. ESC Heart Failure, 2018, 5, 129-138.	1.4	3
56	Nitrosative Stress as a Modulator of Inflammatory Change in a Model of Takotsubo Syndrome. JACC Basic To Translational Science, 2018, 3, 213-226.	1.9	36
57	International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. European Heart Journal, 2018, 39, 2032-2046.	1.0	972
58	International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. European Heart Journal, 2018, 39, 2047-2062.	1.0	521
59	Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 72, 721-733.	1.2	31
60	ADAM-15 and glycocalyx shedding: a new perspective on sepsis-related vasomotor dysfunction. Cardiovascular Research, 2018, 114, 1694-1695.	1.8	3
61	Can We Improve Long-Term Outcomes Postbifurcation Stenting by Prolonged Dual Antiplatelet Therapy?. Circulation: Cardiovascular Interventions, 2018, 11, e006922.	1.4	2
62	Long-Term Prognosis of Patients With Takotsubo Syndrome. Journal of the American College of Cardiology, 2018, 72, 874-882.	1.2	224
63	Signal transduction pathways initiated by catecholamines in takotsubo syndrome: focus on nitrosative stress and energetic impairment. , 2018, , 1283-1286.		0
64	Cangrelor With and Without GlycoproteinÂIIb/IIIa Inhibitors inÂPatientsÂUndergoing PercutaneousÂCoronary Intervention. Journal of the American College of Cardiology, 2017, 69, 176-185.	1.2	47
65	Early Use of N-acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segmentâ€“Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction]). Circulation, 2017, 136, 894-903.	1.6	108
66	Glycocalyx shedding is markedly increased during the acute phase of Takotsubo cardiomyopathy. International Journal of Cardiology, 2017, 243, 296-299.	0.8	35
67	Alterations in Cardiac Deformation, Timing ofÂContraction and Relaxation, and Early Myocardial Fibrosis Accompany the Apparent Recovery of Acute Stress-Induced (Takotsubo) Cardiomyopathy: An End to the Concept ofÂTransience. Journal of the American Society of Echocardiography, 2017, 30, 745-755.	1.2	91
68	Author's Reply. Journal of the American Society of Echocardiography, 2017, 30, 1042.	1.2	1
69	Inorganic Nitrate in Angina Study: A Randomized Doubleâ€Blind Placeboâ€Controlled Trial. Journal of the American Heart Association, 2017, 6, .	1.6	11
70	Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. International Journal of Cardiology, 2017, 227, 443-449.	0.8	3
71	Vitamin D supplementation lowers thrombospondin-1 levels and blood pressure in healthy adults. PLoS ONE, 2017, 12, e0174435.	1.1	13
72	Report from the Annual Conference of the British Society of Echocardiography, November 2016, Queen Elizabeth II Conference Centre, LondonForewordNational Invited Lecture 2016Echo Research and Practice sessionAbstract 1: Left ventricular mechano-temporal alterations during the apparent recovery of acute stress-induced (Tako-tsubo) cardiomyopathyAbstract 2: Right ventricular structure and function in veteran ultrarunners: is there evidence for chronic maladaptation?Abstract 3: Feasibility, efficacy and safety. Journal of Animal Science and Technology, 2017, 4, M1-M18.	0.8	0

#	Article	IF	Citations
73	Platelet Reactivity Is Independent of Left Atrial Wall Deformation in Patients with Atrial Fibrillation. Mediators of Inflammation, 2016, 2016, 1-5.	1.4	4
74	Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit. Therapeutic Drug Monitoring, 2016, 38, 73-78.	1.0	12
75	Approaches for Overcoming Diabetes-Induced Cardiovascular Nitric Oxide Resistance. Free Radical Biology and Medicine, 2016, 100, S150-S151.	1.3	0
76	Emerging drugs for the treatment of angina pectoris. Expert Opinion on Emerging Drugs, 2016, 21, 365-376.	1.0	13
77	A randomized double-blind placebo-controlled crossover trial of sodium nitrate in patients with stable angina INAS. Future Cardiology, 2016, 12, 617-626.	0.5	4
78	Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure. Drugs, 2016, 76, 1337-1348.	4.9	35
79	New Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications. Cardiovascular Drugs and Therapy, 2016, 30, 505-513.	1.3	8
80	Drugs that Affect Cardiac Metabolism: Focus on Perhexiline. Cardiovascular Drugs and Therapy, 2016, 30, 399-405.	1.3	21
81	Cardiovascular Health in Anxiety or Mood Problems Study (CHAMPS): study protocol for a randomized controlled trial. Trials, 2016, 17, 18.	0.7	11
82	New-onset atrial fibrillation and thromboembolic risk: Cardiovascular syzygy?. Heart Rhythm, 2016, 13, 1355-1361.	0.3	16
83	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart, 2016, 102, 508-517.	1.2	67
84	Platelet hyperaggregability in patients with atrial fibrillation. Herz, 2016, 41, 57-62.	0.4	11
85	Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillation. Journal of Geriatric Cardiology, 2016, 13, 202-8.	0.2	4
86	Relation of Delayed Recovery of Myocardial Function After Takotsubo Cardiomyopathy to Subsequent Quality of Life. American Journal of Cardiology, 2015, 115, 1085-1089.	0.7	43
87	Suppression of neutrophil superoxide generation by <scp>BNP</scp> is attenuated in acute heart failure: a case for â€˜<scp>BNP</scp> resistanceâ€™. European Journal of Heart Failure, 2015, 17, 475-483.	2.9	11
88	Reversal of Hyperglycemia: Effects on Nitric Oxide Signaling. American Journal of Medicine, 2015, 128, 427-430.	0.6	6
89	Panic disorder and incident coronary heart disease: a systematic review and meta-analysis protocol. Systematic Reviews, 2015, 4, 33.	2.5	9
90	Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1/adenylate cyclase signalling. Thrombosis Research, 2015, 136, 308-314.	0.8	8

#	Article	IF	Citations
91	Role of aldehyde dehydrogenase in hypoxic vasodilator effects of nitrite in rats and humans. British Journal of Pharmacology, 2015, 172, 3341-3352.	2.7	12
92	Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium. European Journal of Clinical Pharmacology, 2015, 71, 1485-1491.	0.8	10
93	Tako-Tsubo Cardiomyopathy: A Heart Stressed Out of Energy?. JACC: Cardiovascular Imaging, 2015, 8, 985-987.	2.3	57
94	Impaired platelet nitric oxide response in patients with new onset atrial fibrillation. International Journal of Cardiology, 2015, 179, 160-165.	0.8	24
95	Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score. American Journal of Cardiovascular Disease, 2015, 5, 101-9.	0.5	0
96	Dissociation of Early Shock in Takotsubo Cardiomyopathy from either Right or Left Ventricular Systolic Dysfunction. Heart Lung and Circulation, 2014, 23, 1141-1148.	0.2	27
97	Aging of the Nitric Oxide System: Are We as Old as Our NO?. Journal of the American Heart Association, 2014, 3, .	1.6	67
98	Bâ€Type natriuretic peptide suppression of neutrophil superoxide generation: mechanistic studies in normal subjects. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 739-743.	0.9	8
99	Takotsubo cardiomyopathy presenting as Sâ€“T elevation myocardial infarction: Not gone but forgotten?. International Journal of Cardiology, 2014, 172, e261-e262.	0.8	12
100	Meta-Analysis of Clinical Correlates of Acute Mortality in Takotsubo Cardiomyopathy. American Journal of Cardiology, 2014, 113, 1420-1428.	0.7	175
101	Homoarginine and 3-nitrotyrosine in patients with takotsubo cardiomyopathy. International Journal of Cardiology, 2014, 173, 546-547.	0.8	26
102	Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy. International Journal of Cardiology, 2014, 174, 696-701.	0.8	207
103	Thioredoxin-Interacting Protein: Pathophysiology and Emerging Pharmacotherapeutics in Cardiovascular Disease and Diabetes. Cardiovascular Drugs and Therapy, 2014, 28, 347-360.	1.3	76
104	Role of Echocardiography in Tako-Tsubo Cardiomyopathy. JACC: Cardiovascular Imaging, 2014, 7, 130-132.	2.3	3
105	Interaction of Terbinafine (Anti-fungal agent) with Perhexiline: A Case Report. Heart Lung and Circulation, 2014, 23, e149-e151.	0.2	10
106	Hypoxic potentiation of nitrite effects in human vessels and platelets. Nitric Oxide - Biology and Chemistry, 2014, 40, 36-44.	1.2	19
107	Reciprocal regulation of NO signaling and TXNIP expression in humans: Impact of aging and ramipril therapy. International Journal of Cardiology, 2013, 168, 4624-4630.	0.8	36
108	Enhanced NO Signaling in Patients with Takotsubo Cardiomyopathy: Short-Term Pain, Long-Term Gain?. Cardiovascular Drugs and Therapy, 2013, 27, 541-547.	1.3	32

#	Article	IF	Citations
109	Dissociation Between Severity of Takotsubo Cardiomyopathy and Presentation With Shock or Hypotension. Clinical Cardiology, 2013, 36, 401-406.	0.7	45
110	Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRI. Heart, 2012, 98, 1278-1284.	1.2	100
111	Can we make sense of takotsubo cardiomyopathy? An update on pathogenesis, diagnosis and natural history. Expert Review of Cardiovascular Therapy, 2012, 10, 215-221.	0.6	19
112	Occurrence of Tako-Tsubo Cardiomyopathy in Association with Ingestion of Serotonin/Noradrenaline Reuptake Inhibitors. Heart Lung and Circulation, 2012, 21, 203-205.	0.2	45
113	Ramipril Sensitizes Platelets to Nitric Oxide. Journal of the American College of Cardiology, 2012, 60, 887-894.	1.2	46
114	Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.	13.9	7,537
115	Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. British Journal of Pharmacology, 2011, 162, 722-732.	2.7	35
116	N-Terminal Pro-Brain Natriuretic Protein Levels in Takotsubo Cardiomyopathy. American Journal of Cardiology, 2011, 108, 1316-1321.	0.7	123
117	Modulation of myocardial metabolism: an emerging therapeutic principle. Current Opinion in Cardiology, 2010, 25, 329-334.	0.8	46
118	Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2010, 24, 131-137.	1.3	10
119	Apixaban for Reduction In Stroke and Other ThromboembоLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal, 2010, 159, 331-339.	1.2	407
120	Correlates of arterial stiffness in an ageing population: Role of asymmetric dimethylarginine. Pharmacological Research, 2009, 60, 503-507.	3.1	13
121	Is there still a role for treatment with Î²-adrenoceptor antagonists in post-myocardial infarction patients with well-preserved left ventricular systolic function?. Acute Cardiac Care, 2008, 10, 144-147.	0.2	3
122	Potentiation of platelet responsiveness to nitric oxide by angiotensin-(1â€“7) is associated with suppression of superoxide release. Platelets, 2007, 18, 158-164.	1.1	9
123	The Deleterious Effects of Hyperglycemia on Platelet Function in Diabetic Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2007, 49, 304-310.	1.2	138
124	An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: Methodological considerations. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 851, 42-50.	1.2	91
125	Perhexiline. Cardiovascular Drug Reviews, 2007, 25, 76-97.	4.4	152
126	Impaired tissue responsiveness to organic nitrates and nitric oxide: A new therapeutic frontier?. , 2007, 116, 287-305.		87

#	Article	IF	Citations
127	Attenuation of the Negative Inotropic Effects of Metoprolol at Short Cycle Lengths in Humans. Journal of the American College of Cardiology, 2006, 48, 1234-1241.	1.2	9
128	Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation. European Journal of Pharmacology, 2006, 531, 13-19.	1.7	39
129	Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance. British Journal of Clinical Pharmacology, 2005, 60, 355-363.	1.1	22
130	Platelet Nitric Oxide Responsiveness. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2661-2666.	1.1	76
131	Metabolic Modulation With Perhexiline in Chronic Heart Failure. Circulation, 2005, 112, 3280-3288.	1.6	322
132	Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. European Heart Journal, 2004, 25, 634-641.	1.0	148
133	Tolerance Induction During Therapy with Long-Acting Nitrates: How Extensive is the â€œCollateral Damageâ€?. Cardiovascular Drugs and Therapy, 2004, 18, 11-12.	1.3	7
134	Determination of l-arginine and NG,NG- and NG,NGâ€²-dimethyl-l-arginine in plasma by liquid chromatography as AccQ-Fluorâ„¢ fluorescent derivatives. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 805, 325-329.	1.2	86
135	The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. Journal of the American College of Cardiology, 2004, 44, 57-62.	1.2	102
136	Amelioration of nitrate tolerance: matching strategies with mechanisms**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. Journal of the American College of Cardiology, 2003, 41, 2001-2003.	1.2	13
137	Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. American Heart Journal, 2003, 146, 84-90.	1.2	151
138	The Coronary Slow Flow Phenomenon â€“ A New Coronary Microvascular Disorder. Cardiology, 2002, 97, 197-202.	0.6	237
139	Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide. American Journal of Cardiology, 2002, 90, 551-554.	0.7	38
140	Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. Journal of the American College of Cardiology, 2001, 37, 1851-1857.	1.2	73
141	Heart failure in older people: the epidemic we had to have. Medical Journal of Australia, 2001, 174, 432-433.	0.8	6
142	Acute Coronary Findings at Autopsy in Heart Failure Patients With Sudden Death. Circulation, 2000, 102, 611-616.	1.6	298
143	Nitrate Resistance In Platelets From Patients With Stable Angina Pectoris. Circulation, 1999, 100, 129-134.	1.6	87
144	Early treatment with verapamil or diltiazem in patients with acute myocardial infarction: safety and possible beneficial effects. Cardiovascular Drugs and Therapy, 1999, 13, 309-314.	1.3	2

#	Article	IF	Citations
145	Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses. European Journal of Pharmacology, 1998, 356, 207-213.	1.7	10
146	Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochemical Pharmacology, 1996, 52, 273-280.	2.0	204
147	Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 520-525.	1.4	20
148	N -Acetylcysteine in Combination With Nitroglycerin and Streptokinase for the Treatment of Evolving Acute Myocardial Infarction. Circulation, 1995, 92, 2855-2862.	1.6	135
149	The Prevalence of ST-Segment Depression on Ambulatory Electrocardiographic Monitoring During Daily Life in High-Risk Asymptomatic Police Officers. European Journal of Cardiovascular Prevention and Rehabilitation, 1994, 1, 143-148.	3.1	1